Related Experiment Video
Updated: Aug 14, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Impact of ketogenic diet therapy on growth in children with epilepsy
Serena Lu1, Helena Champion2, Nicole Mills2
1UCL, London, United Kingdom.
Insights
Ketogenic diet therapy (KDT) can impact linear growth in children with epilepsy, with effects most pronounced in younger, non-ambulatory individuals on classical KDT. However, catch-up growth is observed after discontinuing the diet.
Area of Science:
- Pediatric Neurology
- Nutritional Science
- Epilepsy Management
Background:
- Ketogenic diet therapy (KDT) is a recognized treatment for drug-resistant epilepsy in children.
- Evidence regarding KDT's effect on pediatric growth remains conflicting.
- This study investigates KDT's impact on linear growth and weight in UK children.
Purpose of the Study:
- To assess the effects of KDT on linear growth and weight in children with epilepsy.
- To identify clinical or demographic factors associated with growth changes during KDT.
- To provide data for informed discussions about KDT's potential growth implications.
Main Methods:
- Retrospective review of medical records from 3 UK epilepsy centers.
- Analysis of height and weight z-scores at baseline, during KDT (1-8 years), and 1-year post-diet.
- Statistical analysis using Wilcoxon Signed Rank, Mann-Whitney, Kruskal-Wallis, and Spearman's Rank correlation tests.
Main Results:
- Significant decrease in median height z-score observed at 1, 2, and 3 years on KDT.
- No significant height or weight z-score changes 1 year after discontinuing KDT.
- Greater height z-score reduction noted in non-ambulatory children, those on classical KDT, and younger children.
- Weight z-score decreased significantly at 4 and 6 years on diet in a subset of patients.
Conclusions:
- KDT can adversely affect linear growth in children, particularly in the initial 3 years.
- Catch-up growth occurs after KDT discontinuation.
- Non-ambulatory status, younger age, and classical KDT may increase growth vulnerability.
- Close monitoring and discussion of potential short-term growth impacts are crucial for families considering KDT.
Rationale:
Ketogenic diet therapy (KDT) is an effective treatment for drug-resistant epilepsy in children. There is conflicting evidence regarding the impact of KDT on growth. We aimed to determine whether linear growth and weight were affected in children who followed KDT in the UK, and to explore potential associations with clinical or demographic factors with impacted growth.
Methods:
A retrospective review of medical records of children with epilepsy following KDT at 3 UK centres was conducted. Height and weight measurements taken as part of routine clinical management were recorded at baseline, 1-8 years on diet, and 1-year post-diet. Measurements were converted into z-scores, and the differences from baseline analysed using Wilcoxon Signed Rank tests. Potential associations of impacted growth with feeding method, ambulatory status, diet type, age at diet onset and average daily protein intake were investigated using Mann-Whitney, Kruskal-Wallis tests or Spearman's Rank correlation.
Results:
265 individuals were included, of which 84 had post-diet data available. Median height z-score significantly decreased at 1- (n = 139, p = .018), 2- (n = 86, p < .0005) and 3 years (n = 27, p = .001) on diet. There was no significant change to height or weight z-score 1-year post-diet discontinuation. Median weight z-score significantly decreased from baseline at 4 years (n = 15, p = .020), and 6 years (n = 8, p = .025) on diet, but not at other time points. There was greater height z-score decrease in non-ambulatory children at 2 years (p = .009), in those following a classical diet compared with the modified ketogenic diet at 2 years (p = .006) and amongst younger children at 2 years (n = 86, p < .005) and 3 years (n = 27, p = .008) on diet. No significant differences were found in weight z-score change across any subgroup, following Bonferroni correction for multiple testing.
Conclusions:
Median linear growth was significantly adversely affected for the first 3 years on KDT but catch-up growth post diet discontinuation was observed. Non-ambulatory children, younger children, and individuals following a classical diet may be more vulnerable to impacted growth when on KDT, although this was not consistent across all time points. The potential short-term impact on linear growth should be discussed with individuals considering KDT, and monitored closely.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
05:42Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Electroconvulsive Therapy
Chronic Kidney Disease III: Interprofessional Care
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...